Influence of esomeprazole on the pharmacodynamic activity of thiazolidinediones (pioglitazone and rosiglitazone) in animal Models
More details
Hide details
Department of Pharmaceutics, Bharati Vidhyapeeth College of Pharmacy, Kolhapur-416013,Maharashtra, India
Post Graduate Department of Pharmacology and Research Center, H.S.K. College Of Pharmacy, Bagalkot Karnataka-587101, India
Prashant D Phadatare   

Department of Pharmaceutics, Bharati Vidhyapeeth College of Pharmacy, Kolhapur-416013,Maharashtra, India
J Pre Clin Clin Res. 2016;10(2):110–114
Drug-drug interaction studies are essential building blocks in drug development. Thiazolidinediones (TZDs: pioglitazone, and rosiglitazone) are peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, which have been widely used in the treatment of type 2 diabetes as insulin sensitizers. Esomeprazole, the (S) -isomer of omeprazole, is the first proton pump inhibitor (PPI) developed as a single isomer for the treatment of acid-peptic disease by specific inhibition of H+K+- ATPase in gastric parietal cells. The role of esomeprazole on the pharmacodynamic activity of TZDs is not currently known; however, there is the possibility of drug interaction (DI) leading to decreased activity of TZDs. The study was planned to investigate the safety and effectiveness of TZDs therapy in the presence of esomeprazole in animal models
Kilari Eswar Kumar, Shaik Mastan. Influence of Efavirenz and Nevirapine on the Pharmacodynamics and Pharmacokinetics of Gliclazide in Rabbits. J Endocrinol Metab. 2011; 1(3): 113–124.
Pietzsch M, Theuer S, Haase G, Plath F. Results of systemic screening for serious gastrointestinal bleeding associated with NSAIDs in Rostock hospitals. Int J Clin Pharmacol Ther. 2002; 40: 111–115.
Burghen GA, Murrel LR, Whitington GL, Klyce MK, Burstein S. Acid peptic diseases in children with type-I diabetes mellitus. A complicating relationship. Am J Dis Child. 1992; 146: 718–22.
Mastan SK, Eswar Kumar K. Effect of antiretroviral drugs on the pharmacodynamics of Gliclazide with respect to glucose–insulin homeostasis in animal models. J Experimental Pharmacol. 2010; 2: 1–11.
Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075–1078.
Esplugues JV, Marthi-Cabrera M, Ponce J. Safety of proton pump inhibitors. Med Clin. (Barc) 2006; 127: 790–95.
Larsson H, Carlsson E, Junggren U, Olbe L, Sjostrand SE, Skanberg I, Sundell G. Inhibition of gastric acid secretion by omeprazole in dog and rat. Gastroenterology 1983; 85: 900–07.
Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura H, Maki Y. Antisecretory and antiulcer activites of a novel proton pump inhibitors AG-1749 in dogs and rats. J Pharmacol Exp Ther. 1989; 248: 806–15.
Salim MA, Bastaki, Irwin S, Chandranath, Jaipaul Singh. The anti-secretary and anti-ulcer activities of esomeprazole in comparison with omeprazole in stomach of rats and rabbits. Mol Cell Biochem. 2008; 309: 167–75.
Paget GE, Barnes JM: From toxicity tests.In evaluation of drug activities: pharmacometrics. Edited by: Laurence DR, BacharachAL. London: Academic Press; 1964; 1(1): 050–161.
Suresh Janadri, S. Ramachandra Setty, M D Kharya. Influence of itraconazole on antidiabetic effect of thiazolidinedione in diabetic rats. Int J Pharm Pharmaceutical Sci. 2009; 1(1): 119–124.
Riley V. Adaption of orbital bleeding technique to rapid serial blood studies. Proc Soc Exp Bio Med. 1960; 104: 751–54.
Prashant PD, Chandrashekhar VM. Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits. Mol Cell Biochem. 2011; 354: 135–40.
Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non carcinogenicchemogen. J Clin Pathol. 1969; 22: 158–161.
Venkatesh S, Reddy GD, Reddy BM, Ramesh M, Rao AV. Antihyperglycemic activity of Caralluma attenuate. Fitoterpia. 2003; 74: 274–279.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–419.
David AW. In Foye’s Principles of Medicinal Chemistry, Edited by Thomas LL and David AW,Drug Metabolism. Philadelphia: Lippincott Williams and Wilkin 2008; 6: 253–326.
Mohammed YM, Mohammed EI, Mohiunddin N, Syeda SS. Interaction of rosiglitazone and antiarrthmic drugs in animal model. Ann Med Health Sci Res. 2012; 2(2): 155–156.
Shitole PP, Badole SL, Bodhankar SL, Mohan V, Bhaskaran S. Anti-hyperglycaemic activity of IND 01 and its interaction with glyburide and pioglitazone in alloxan induced diabetic mice. Int J Diabetes & Metabolism 2009; 17: 21–26.
Bangui LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Ann Rev Med. 2006; 57: 265–281.
Richardson H, Campbell SC, Smith SA, Macfarlane WM. Effects of rosiglitazone and metformin on pancreatic beta cell gene expression. Diabetol. 2006; 49(4): 685–696.
Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care. 2004; 27(11): 2585–2589.
Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23(1): 57–63.
Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S) -isomer of omeprazole. Clin Pharmacokinet. 2001; 40: 523–37.
Kumar KS, Amrit P, Devendra S, Baganal P, Rajendra SV, Ramachandra SS. Influence of metronidazole on hypoglycemic activity of thiazolidinedione normal and alloxan induced diabetic rats. Indian J Pharma Educ Res. 2009; 3: 91–95.